Ergomed PLC (LON:ERGO) insider Richard Barfield purchased 64,000 shares of Ergomed stock in a transaction dated Wednesday, June 12th. The shares were purchased at an average cost of GBX 270 ($3.53) per share, for a total transaction of £172,800 ($225,793.81).

Richard Barfield also recently made the following trade(s):

  • On Friday, June 7th, Richard Barfield purchased 36,000 shares of Ergomed stock. The shares were purchased at an average cost of GBX 241 ($3.15) per share, for a total transaction of £86,760 ($113,367.31).

ERGO stock opened at GBX 286 ($3.74) on Friday. The company has a market cap of $133.11 million and a PE ratio of -14.30. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.41 and a current ratio of 1.48. Ergomed PLC has a one year low of GBX 145 ($1.89) and a one year high of GBX 258 ($3.37).

Separately, Numis Securities reaffirmed a “buy” rating and set a GBX 267 ($3.49) price target (up previously from GBX 190 ($2.48)) on shares of Ergomed in a research report on Thursday, May 16th.

WARNING: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2019/06/16/insider-buying-ergomed-plc-lonergo-insider-purchases-64000-shares-of-stock.html.

About Ergomed

Ergomed plc provides clinical research, and drug development and safety and medical information services in the United Kingdom and internationally. The company offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies.

Recommended Story: Producer Price Index (PPI)

Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with MarketBeat.com's FREE daily email newsletter.